Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...ch will be presented on November 19 and is of inte...y processing, will deal with the application of th...micro scale flow chemistry equipment. Professor L...ized with several prestigious prizes and awards, i... , Columbia, MD (PRWEB) N...
(Date:11/4/2009)...irstCall/ -- Star Scientific, Inc . (Nasdaq: S...troduce the CigRx(TM) nutraceutical product develo... for worldwide marketing and sales in partnership ...Ventiv Health offers a complete range of commercia...lifecycle, in a range of healthcare categories tha...
(Date:11/4/2009)...e-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR...ird quarter ended September 30, 2009. ,, Net l...ved to $31.0 million or $0.33 per share, as compar...re in the third quarter of 2008. ,, Nektar c...iciencies as compared to a year ago. Total operat...
(Date:11/4/2009)...ire/ -- Health Robotics today announced,the worldw...rkflow Engine at,the American Society of Health-Sy...n Las Vegas. With the availability of the i.v.SOFT...t and only company in the world to provide a,total... process control and,patient safety in the I.V. Ro...
Breaking Biology Technology:Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3
...SAN DIEGO, March 2 BioMed Realty Trust, Inc. (NYS...cutive management will present at the Citi 2009 Gl... approximately 9:05 a.m. Eastern Standard Time on ...ll be open to all investors by calling 719.785.559...ioMed Realty Trust , BioMed Realty Trust, Inc. is...
..., Innovative B.C. Technology Promises to Revolu...ER, March 2 /PRNewswire-FirstCall/ - EnWave Corpor...ay announced that it has completed the first sale ...uipment to CAL-SAN Enterprises, Ltd. of Richmond, ...producers. With this sale, EnWave has proven that ...
... EXTON, Pa., March 2 Morphotek(R), Inc., a sub...ay announced that it has commenced a,multi-centere...ody in,mesothelioma. The study will evaluate MORAb...isplatinum, as a first-line treatment for patients... the study is to assess the efficacy of MORAb-009,...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3
(Date:11/4/2009)...an has received more than $10 million in research ...ederal stimulus program, bringing thetotal amount ...$23 million. Thirty-three projects achieved stimu...o weather. , "The university has thoughtfully un... scholarly excellence to federal agency priorities...
(Date:11/4/2009)...re/ -- What,s the cost of saving a teenage life? W...ing from prescription medication abuse, there,s no... may be unaware that the lock-boxes they,ve instal...g timebomb of prescription drugs. That,s why MEDNE...l supplies, has formed an exclusive partnership wi...
(Date:11/4/2009)...wswire/ -- GenVault Corporation (Carlsbad, CA) tod...joined its Board of Directors. Dr. Brody, the Irw..., is an acclaimed physician-scientist and universi...r. Brody served as president of The Johns Hopkins ...y of Engineering and the Institute of Medicine, an...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Hormone therapy may confer more aggressive properties to prostate tumors 48453 1Drugs against winter vomiting disease one step closer 48451 1Drugs against winter vomiting disease one step closer 48451 2New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 1New Jefferson study may redefine how a chronic auto immune disease is diagnosed 48449 2
...A - GEOLOGY topics span the globe and beyond, co...stones and shales of Scotland, a "Greenhouse World... Greenland, oxidation of methane in southern Namib..., gold nanoparticles in Australia, and the possibi...SA TODAY contains the first authoritative geologi...
...June 20, 2008) The future of high-intensity x-ray...ts at U.S. Department of Energy,s Argonne National...tion light sources. , "The free electron laser os...ys up to one hundred million times brighter than c...d fellow Kwang-Je Kim said. , Current technology ...
... by a scientist from The University of Western Ont...ecades-old evolutionary doctrines long accepted as...d Dawkins ("The God Delusion") introduced the conc...world over have hailed the theory as a natural ext...ing genomes, the word ,selfish, does not refer to ...
Other Biology News:July 2008 GEOLOGY and GSA Today media highlights 2July 2008 GEOLOGY and GSA Today media highlights 3July 2008 GEOLOGY and GSA Today media highlights 4July 2008 GEOLOGY and GSA Today media highlights 5July 2008 GEOLOGY and GSA Today media highlights 6July 2008 GEOLOGY and GSA Today media highlights 7July 2008 GEOLOGY and GSA Today media highlights 8A novel X-ray source could be brightest in the world 2
Mouse Anti-Human E1A (adenovirus early region 1) Monoclonal Antibody, Unconjugated, Clone M73 from Exalpha Biologicals, Inc.
Blocking Reagent, TBS with 1% BSA from Bethyl Laboratories
Anti-Presenilin-1, N-terminus Polyclonal Antibody, Unconjugated from CHEMICON
RayBio Human Chemokine Antibody Array I & 1.1 Service from Raybiotech, Inc.
Biology Products: